Submitted Variants of Uncertain Significance (VUS) will be assessed by our Clinical Advisory Board (CAB; see below) who will meet at least twice a year.
They will consider and rank the submitted VUS based on the following Congenital Anomalies Cluster priorities (in order of importance):
- New disease gene
- Known disease gene, but new phenotype association or novel allelic disorder
- Known disease gene with difficult to interpret VUS, eg nearby SV, deep intronic SNV
- Known disease gene where deep phenotypic investigation of the mouse model could lead to new insights into pathogenic mechanisms
- Contributing teams are ideally clinically led or with strong clinical engagement, in order to efficiently return diagnostic information and enable further assessment of patient phenotypes.
- The clinical features of your patient should be present at birth and overlap with the specialities of our developmental biology team: craniofacial, skeletal, heart, neural tube, kidney, ciliopathies.
- More weight will be given to syndromic conditions to simultaneously study multiple systems in the mouse.
To submit a VUS, please visit the submissions portal.